These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 14766884)

  • 61. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
    Dagi HT; Findik D; Senkeles C; Arslan U
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interaction of carvacroland voriconazole against drug - resistant Candida strains isolated from patients with candidiasis.
    Sharifzadeh A; Shokri H; Abbaszadeh S
    J Mycol Med; 2019 Apr; 29(1):44-48. PubMed ID: 30554935
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.
    Pfaller MA; Diekema DJ; Messer SA; Boyken L; Huynh H; Hollis RJ
    J Clin Microbiol; 2002 May; 40(5):1694-7. PubMed ID: 11980944
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.
    Pfaller MA; Hata K; Jones RN; Messer SA; Moet GJ; Castanheira M
    Diagn Microbiol Infect Dis; 2011 Oct; 71(2):167-70. PubMed ID: 21696907
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.
    Chryssanthou E; Cuenca-Estrella M
    J Clin Microbiol; 2002 Oct; 40(10):3841-4. PubMed ID: 12354895
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.
    Pfaller MA; Barry A; Bille J; Brown S; Ellis D; Meis JF; Rennie R; Rinaldi M; Rogers T; Traczewski M
    J Clin Microbiol; 2004 Apr; 42(4):1716-8. PubMed ID: 15071030
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
    Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Killian S; Norris HA; Ghannoum MA
    J Clin Microbiol; 1999 Mar; 37(3):591-5. PubMed ID: 9986817
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.
    Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN
    J Clin Microbiol; 2001 Nov; 39(11):3952-4. PubMed ID: 11682513
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.
    Li Y; Nguyen MH; Derendorf H; Cheng S; Clancy CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2985-7. PubMed ID: 17517840
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative evaluation of macrodilution and alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates.
    To WK; Fothergill AW; Rinaldi MG
    J Clin Microbiol; 1995 Oct; 33(10):2660-4. PubMed ID: 8567901
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
    Lee SC; Lo HJ; Fung CP; Lee N; See LC
    J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Susceptibility to azoles and amphotericin B of isolates of Candida spp. Experience of a university health network, between 2004 and 2010].
    Porte L; León P; Gárate C; Guzmán AM; Labarca J; García P
    Rev Chilena Infectol; 2012 Apr; 29(2):149-55. PubMed ID: 22689028
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antifungal susceptibility testing of a 10-year collection of Candida spp. isolated from patients with candidemia.
    Iatta R; Caggiano G; Cuna T; Montagna MT
    J Chemother; 2011 Apr; 23(2):92-6. PubMed ID: 21571625
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro activity of voriconazole against Prototheca wickerhamii: comparative evaluation of sensititre and NCCLS M27-A2 methods of detection.
    Linares MJ; Solís F; Casal M
    J Clin Microbiol; 2005 May; 43(5):2520-2. PubMed ID: 15872301
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
    Samra Z; Yardeni M; Peled N; Bishara J
    Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.
    Pfaller MA; Boyken LB; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Apr; 49(4):1274-9. PubMed ID: 21289155
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
    Diekema DJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Kroeger J; Jones RN; Pfaller MA
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):233-6. PubMed ID: 19070452
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital.
    Passos XS; Costa CR; Araújo CR; Nascimento ES; e Souza LK; Fernandes Ode F; Sales WS; Silva Mdo R
    Mycopathologia; 2007 Mar; 163(3):145-51. PubMed ID: 17334813
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antifungal susceptibility of Candida species using the Clinical and Laboratory Standards Institute disk diffusion and broth microdilution methods.
    Noake T; Kuriyama T; White PL; Potts AJ; Lewis MA; Williams DW; Barnes RA
    J Chemother; 2007 Jun; 19(3):283-7. PubMed ID: 17594923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.